Show simple item record

dc.contributor.authorSagdeo, Amol
dc.contributor.authorAskari, Ayman
dc.contributor.authorMorrissey, Hana
dc.contributor.authorBall, Patrick
dc.date.accessioned2020-10-15T10:19:50Z
dc.date.available2020-10-15T10:19:50Z
dc.date.issued2020-12-31
dc.identifier.citationSagdeo, A., Askari, A., Morrissey, H. and Ball, P. (in press) Baricitinib in rheumatoid arthritis – real world cross-sectional study, Open Rheumatology Journalen
dc.identifier.issn1874-3129en
dc.identifier.urihttp://hdl.handle.net/2436/623717
dc.descriptionThis is an accepted manuscript of an article published by Bentham Open in The Open Rheumatology Journal (in press). The accepted version of the publication may differ from the final published versionen
dc.description.abstractIntroduction: Rheumatoid arthritis (RA) is the most common cause of inflammatory polyarthritis. In RA, increased circulating levels of pro-inflammatory cytokines contribute to the overall symptomatology of fatigue, pain, and joint stiffness. Baricitinib is an orally administered biologic DMARD, used in RA patients, inhibiting signaling via JAK1/JAK2 inhibition, reducing the release of pro-inflammatory cytokines. Objective: To explore the efficacy and tolerability for baricitinib in a local population. Methods: A cross-sectional study was carried out to review data of RA patients on Baricitinib from the researchers’ own clinic, since its approval in August 2017. The data was collected from an anonymized electronic patient records report. The clinical response was then classified into mild, moderate, and significant improvement. Results and Discussion: Overall, 27 out of 37 patients (72.9%) showed clinical improvement with baricitinib. In 9(24.3%) out of 37 patients, the dose had to be reduced to either 2mg/day or 2mg/day - 4mg/day on alternate days. In four of the 9 patients’ where the dose was reduced due to infections (UTI or sinuses), they subsequently experienced fewer infections while maintaining moderate improvement in their RA. Conclusion: There is a need for longer-term and larger studies to evaluate the full side effects profile of baricitinib in the local population.en
dc.formatapplication/pdfen
dc.languageEnglish
dc.language.isoenen
dc.publisherBentham Openen
dc.relation.urlhttps://benthamopen.com/TORJ/home/en
dc.subjectRheumatoid arthritis (RA)en
dc.subjectJanus associated kinase (JAK)en
dc.subjectBaricitiniben
dc.subjectconventional disease modifying drugs (cDMARD’s)en
dc.subjectBiologic disease modifying drugs (bDMARD’s),en
dc.titleBaricitinib in rheumatoid arthritis – real world cross-sectional studyen
dc.typeJournal articleen
dc.identifier.eissn1874-3129
dc.identifier.journalOpen Rheumatology Journalen
dc.date.updated2020-10-12T08:21:07Z
dc.date.accepted2020-10-02
rioxxterms.funderUniversity of wolverhamptonen
rioxxterms.identifier.projectUOW15102020HMen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2020-12-31en
refterms.dateFCD2020-10-15T10:17:06Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
TORJ-20100801-Corrections ...
Embargo:
2020-12-31
Size:
252.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/